California Controversy: Let's Not Expand the Market in Women's Eggs
By Marcy Darnovsky and Susan Berke Fogel,
Huffington Post
| 09. 03. 2013
Last month, California Governor Jerry Brown vetoed a bill that would have allowed researchers to pay women for having their eggs harvested and retrieved. His move was warmly welcomed by women's health and public interest groups including Our Bodies Ourselves, National Women's Health Network, Pro-Choice Alliance for Responsible Research, Alliance for Humane Biotechnology and Center for Genetics and Society. (Disclosure: see author affiliations.)
Echoing the longstanding concerns of many progressives about the serious risks of egg retrieval, Governor Brown's brief but eloquent veto message recognized that "in medical procedures of this kind, genuinely informed consent is difficult because the long term risks are not adequately known." He also acknowledged that low-income women would face disproportionate temptations to discount the risks. "Putting thousands of dollars on the table only compounds the problem," Brown wrote.
The vetoed bill, AB 926, was sponsored by the fertility industry's trade organization, the American Society for Reproductive Medicine. It was supported by several mainstream women's organizations, and breezed through the Democratic-dominated legislature. Ironically, as Governor Brown noted, the law that this bill would have overturned...
Related Articles
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...